AXON Names New CEO, ANTH Awaits Data In Q3, Nicox Gets 2nd Chance From FDA

(RTTNews) - Anthera Pharmaceuticals (ANTH) has completed dosing in its phase II study of Blisibimod in patients with IgA nephropathy, dubbed BRIGHT-SC.

The Company anticipates reporting top-line data from the study next quarter (Q3, 2017).

ANTH closed Monday's trading at $0.41, up 2.42%.

Axovant Sciences (AXON) has appointed David Hung as its Chief Executive Officer, effective April 7, 2017.

Hung was the co-founder, President, and Chief Executive Officer of Medivation, which was acquired by Pfizer for approximately $14 billion in September 2016.

Hung will be paid an annual base salary of $550,000, and is eligible to receive a bonus of at least 60% of his annual base salary. He is also entitled to $115,000 for expenses incurred in connection with his relocation.

Hung will purchase at least $10 million of Axovant's securities in its next financing event, reveals a SEC filing.

Hung succeeds Vivek Ramaswamy who resigned as the Chief Executive Officer of Axovant Sciences. He will continue to serve as member of the Board.

AXON touched a new 52-week high of $19.85 on Monday, before closing the day's trading at $18.54, up 22.54%.

Five Prime Therapeutics Inc. (FPRX) has completed enrollment in its initially planned 30-patient cohort of the phase II part of the ongoing clinical trial of Cabiralizumab for the treatment of pigmented villonodular synovitis.

Pigmented villonodular synovitis is a rare, locally aggressive tumor of the synovium (joint lining).

The Company plans to present initial data from the study at 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.

FPRX closed Monday's trading at $33.84, up 2.92%.

Nicox SA's (NICXF.OB) resubmitted New Drug Application for ZERVIATE for the treatment of ocular itching associated with allergic conjunctivitis has been accepted for review by the FDA - with a decision date set for September 8, 2017.

ZERVIATE was turned down by the FDA last October due to reasons pertaining solely to a Good Manufacturing Practice inspection at a third party facility producing the active pharmaceutical ingredient of ZERVIATE.

The Company has another regulatory catalyst to watch out for this year. Vyzulta, licensed by Nicox to Bausch + Lomb, a wholly-owned subsidiary of Valeant Pharmaceuticals International Inc., awaits the FDA decision on August 24, 2017.

Vyzulta is developed as an intraocular pressure lowering single-agent eye drop for patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).

NICXF.OB closed at a 52-week high of $10.94 on Monday, up 15.77%.

Ohr Pharmaceutical Inc. (OHRP) is planning to amend the ongoing phase III clinical trial of Squalamine in wet-AMD to enable efficacy analyses.

In the study, dubbed MAKO, patients will be randomised to receive their assigned study treatment of monthly Lucentis and either Squalamine or placebo drops twice daily, and undergo scheduled visits and assessments through nine months. The primary endpoint will be an assessment of visual acuity.

The results from the study are anticipated by the end of calendar 2017 or early 2018.

OHRP closed Monday's trading at $0.68, up 2.80%. In after-hours, the stock was up 7.35% to $0.73.